Ainos, Inc. filings document formal disclosures for a Texas public company whose securities include Nasdaq-listed warrants to purchase common stock under AIMDW. The record includes Form 8-K reports covering annual and quarterly results, AI Nose commercial announcements, strategic partnerships, at-the-market common stock offering activity and changes in the company’s independent registered public accounting firm.
Capital-structure disclosures include the completed reverse stock split of Ainos common stock and related adjustments to outstanding options and warrants. The filings also provide exhibits such as press releases, legal opinions, audit-firm correspondence and Inline XBRL cover-page data tied to the company’s reporting, financing, governance and material-event disclosures.
Ainos, Inc. reported Q1 2026 results showing minimal revenue and continued losses while shoring up liquidity with new financing. Revenue was just $161, down sharply from $106,207 a year earlier as the company shifted AI Nose activity from healthcare-adjacent uses toward earlier-stage industrial deployments.
The net loss narrowed to $2,459,800 from $3,286,022, helped by a 30% reduction in operating expenses, especially lower share-based compensation and SG&A. Cash and cash equivalents rose to $2,841,422 from $417,353 at year-end, driven by a new related-party loan of about $2,812,940 and $601,600 of net proceeds from an at-the-market equity program.
Total liabilities increased to $16,389,637, including $11,000,000 of related-party convertible notes, while stockholders’ equity declined to $5,691,946. Management states that recurring losses, an accumulated deficit of $69,980,128, and dependence on future financings create “substantial doubt” about the company’s ability to continue as a going concern.
Ainos, Inc. reported Q1 2026 results showing minimal revenue and continued losses while shoring up liquidity with new financing. Revenue was just $161, down sharply from $106,207 a year earlier as the company shifted AI Nose activity from healthcare-adjacent uses toward earlier-stage industrial deployments.
The net loss narrowed to $2,459,800 from $3,286,022, helped by a 30% reduction in operating expenses, especially lower share-based compensation and SG&A. Cash and cash equivalents rose to $2,841,422 from $417,353 at year-end, driven by a new related-party loan of about $2,812,940 and $601,600 of net proceeds from an at-the-market equity program.
Total liabilities increased to $16,389,637, including $11,000,000 of related-party convertible notes, while stockholders’ equity declined to $5,691,946. Management states that recurring losses, an accumulated deficit of $69,980,128, and dependence on future financings create “substantial doubt” about the company’s ability to continue as a going concern.
Ainos, Inc. reported first quarter 2026 results showing minimal revenue and a narrower loss as it advances its AI Nose commercialization strategy. Revenue for the quarter was $161, compared with $106,207 a year earlier, reflecting the shift toward infrastructure-focused AI Nose deployments still in early stages.
The company reported a net loss of $2.46 million, improving from a $3.29 million loss in the prior-year quarter, as operating expenses declined about 30% year-over-year to approximately $2.28 million. Cash and cash equivalents rose to $2.84 million from $0.42 million, supported by a previously announced NT$90 million (approximately $2.8 million) financing, while total liabilities increased to $16.39 million and stockholders’ equity decreased to $5.69 million.
Operationally, Ainos continued deploying AI Nose under a roughly three-year $2.1 million commercial arrangement in backend semiconductor manufacturing, initiated pilots in front-end semiconductor environments, expanded healthcare infrastructure pilots, and further developed its Smell ID datasets and Smell Language Model to support long-term Smell AI platform commercialization.
Ainos, Inc. reported first quarter 2026 results showing minimal revenue and a narrower loss as it advances its AI Nose commercialization strategy. Revenue for the quarter was $161, compared with $106,207 a year earlier, reflecting the shift toward infrastructure-focused AI Nose deployments still in early stages.
The company reported a net loss of $2.46 million, improving from a $3.29 million loss in the prior-year quarter, as operating expenses declined about 30% year-over-year to approximately $2.28 million. Cash and cash equivalents rose to $2.84 million from $0.42 million, supported by a previously announced NT$90 million (approximately $2.8 million) financing, while total liabilities increased to $16.39 million and stockholders’ equity decreased to $5.69 million.
Operationally, Ainos continued deploying AI Nose under a roughly three-year $2.1 million commercial arrangement in backend semiconductor manufacturing, initiated pilots in front-end semiconductor environments, expanded healthcare infrastructure pilots, and further developed its Smell ID datasets and Smell Language Model to support long-term Smell AI platform commercialization.
Ainos, Inc. director Chiang Yao-Chung reported an open-market purchase of the company’s common stock through an indirect holding. On May 5, 2026, a spouse-related account bought 129 shares at $1.70 per share, bringing this indirect position to 829 shares.
In addition to these indirectly held shares, the reporting person also directly owns 90,880 shares of Ainos common stock as previously disclosed, indicating that the newly reported transaction is small compared with the existing direct holdings.
Ainos, Inc. director Chiang Yao-Chung reported an open-market purchase of the company’s common stock through an indirect holding. On May 5, 2026, a spouse-related account bought 129 shares at $1.70 per share, bringing this indirect position to 829 shares.
In addition to these indirectly held shares, the reporting person also directly owns 90,880 shares of Ainos common stock as previously disclosed, indicating that the newly reported transaction is small compared with the existing direct holdings.
Ainos, Inc. director Chiang Yao-Chung reported two open-market purchases of the company’s common stock through indirect ownership by his spouse. He bought 100 shares at $1.75 per share on April 29, 2026 and 200 shares at $1.68 per share on April 30, 2026, increasing indirect holdings to 700 shares. A footnote states he also directly owns 90,880 shares of Ainos common stock as previously disclosed.
Ainos, Inc. director Chiang Yao-Chung reported two open-market purchases of the company’s common stock through indirect ownership by his spouse. He bought 100 shares at $1.75 per share on April 29, 2026 and 200 shares at $1.68 per share on April 30, 2026, increasing indirect holdings to 700 shares. A footnote states he also directly owns 90,880 shares of Ainos common stock as previously disclosed.
Ainos, Inc. director TSAI CHUN-JUNG received equity compensation through restricted stock units that immediately converted into common shares. On the transaction date, 330,000 RSUs were granted and vested under the Ainos, Inc. 2023 Stock Incentive Plan and then converted into 330,000 shares of common stock at a stated price of $1.61 per share. Following these transactions, TSAI directly holds 686,999 shares of Ainos common stock. These are compensation-related awards rather than open-market purchases or sales.
Ainos, Inc. director TSAI CHUN-JUNG received equity compensation through restricted stock units that immediately converted into common shares. On the transaction date, 330,000 RSUs were granted and vested under the Ainos, Inc. 2023 Stock Incentive Plan and then converted into 330,000 shares of common stock at a stated price of $1.61 per share. Following these transactions, TSAI directly holds 686,999 shares of Ainos common stock. These are compensation-related awards rather than open-market purchases or sales.
Ainos, Inc. director and CEO Tsai Chun-hsien reported equity awards and a conversion on April 15, 2026. He received 300,000 RSUs that vested under the Ainos, Inc. 2023 Stock Incentive Plan, which were then converted into 300,000 shares of Common Stock. A related award entry shows these 300,000 Common shares at $1.61 per share, bringing his directly held Common Stock to 710,372 shares after the transactions. No open-market purchases or sales were reported; all activity reflects compensation-related grants and a derivative conversion.
Ainos, Inc. director and CEO Tsai Chun-hsien reported equity awards and a conversion on April 15, 2026. He received 300,000 RSUs that vested under the Ainos, Inc. 2023 Stock Incentive Plan, which were then converted into 300,000 shares of Common Stock. A related award entry shows these 300,000 Common shares at $1.61 per share, bringing his directly held Common Stock to 710,372 shares after the transactions. No open-market purchases or sales were reported; all activity reflects compensation-related grants and a derivative conversion.
Ainos, Inc. director Lee Ting-chuan reported equity compensation activity involving restricted stock units (RSUs) that converted into common shares. On April 15, 2026, he received 570,000 RSUs granted and vested under the Ainos, Inc. 2023 Stock Incentive Plan, which were then converted into 570,000 shares of common stock at a reported value of $1.61 per share. After these award and conversion transactions, Lee directly holds 935,707 shares of Ainos common stock. These are compensation-related acquisitions rather than open-market purchases or sales.
Ainos, Inc. director Lee Ting-chuan reported equity compensation activity involving restricted stock units (RSUs) that converted into common shares. On April 15, 2026, he received 570,000 RSUs granted and vested under the Ainos, Inc. 2023 Stock Incentive Plan, which were then converted into 570,000 shares of common stock at a reported value of $1.61 per share. After these award and conversion transactions, Lee directly holds 935,707 shares of Ainos common stock. These are compensation-related acquisitions rather than open-market purchases or sales.
ASE Test, Inc., a 10% owner of Ainos, Inc., reported an open-market purchase of 6% Convertible Notes due 2027. The transaction covers 5,994 units of the note, each currently convertible into Ainos common stock at a $22.50 per share conversion price. Following this transaction, ASE Test, Inc. holds 105,868 units of the convertible note. The notes bear 6% compounded interest and have a maturity date extended to March 12, 2027 under an amended agreement.
ASE Test, Inc., a 10% owner of Ainos, Inc., reported an open-market purchase of 6% Convertible Notes due 2027. The transaction covers 5,994 units of the note, each currently convertible into Ainos common stock at a $22.50 per share conversion price. Following this transaction, ASE Test, Inc. holds 105,868 units of the convertible note. The notes bear 6% compounded interest and have a maturity date extended to March 12, 2027 under an amended agreement.
ASE Technology Holding and subsidiary ASE Test, Inc. report beneficial ownership of 667,085 shares of Ainos, Inc. common stock, representing 8.4% of the class. This stake combines 11,777 shares held directly with shares issuable from a $2,000,000 2023 convertible note, a $9,000,000 2024 convertible note, and a warrant for 100,000 shares, all reflecting a one-for-five reverse stock split completed in June 2025. The notes bear 6% compound interest and are convertible primarily at $22.50 per share. ASE Test Taiwan has also granted Ainos KY broad voting discretion over its Ainos shares and agreed to annual transfer limits, underscoring a long-term, structured investment relationship.
ASE Technology Holding and subsidiary ASE Test, Inc. report beneficial ownership of 667,085 shares of Ainos, Inc. common stock, representing 8.4% of the class. This stake combines 11,777 shares held directly with shares issuable from a $2,000,000 2023 convertible note, a $9,000,000 2024 convertible note, and a warrant for 100,000 shares, all reflecting a one-for-five reverse stock split completed in June 2025. The notes bear 6% compound interest and are convertible primarily at $22.50 per share. ASE Test Taiwan has also granted Ainos KY broad voting discretion over its Ainos shares and agreed to annual transfer limits, underscoring a long-term, structured investment relationship.
Ainos, Inc. reported full-year 2025 results and highlighted early commercialization of its AI Nose platform. Revenue reached $124,157, up about 499% from 2024, with gross margin turning positive at roughly 82.9% after a prior-year gross loss.
Despite this top-line growth, Ainos posted a net loss of about $14.8 million, similar to 2024, as operating expenses were roughly $14.1 million. Cash and cash equivalents fell to about $417,353 versus $3.9 million a year earlier. After year-end the company raised NTD 90 million (approximately $2.82 million) to support operations and AI Nose deployment.
For 2026, Ainos is rolling out AI Nose in semiconductor environments, including around 200 systems for front-end wafer fabs and about 1,400 systems under a three-year $2.1 million deployment in semiconductor packaging and testing, with a potential roadmap to scale substantially if validations succeed.
Ainos, Inc. reported full-year 2025 results and highlighted early commercialization of its AI Nose platform. Revenue reached $124,157, up about 499% from 2024, with gross margin turning positive at roughly 82.9% after a prior-year gross loss.
Despite this top-line growth, Ainos posted a net loss of about $14.8 million, similar to 2024, as operating expenses were roughly $14.1 million. Cash and cash equivalents fell to about $417,353 versus $3.9 million a year earlier. After year-end the company raised NTD 90 million (approximately $2.82 million) to support operations and AI Nose deployment.
For 2026, Ainos is rolling out AI Nose in semiconductor environments, including around 200 systems for front-end wafer fabs and about 1,400 systems under a three-year $2.1 million deployment in semiconductor packaging and testing, with a potential roadmap to scale substantially if validations succeed.